UY39714A - Composiciones de vacuna de staphylococcus aureus - Google Patents

Composiciones de vacuna de staphylococcus aureus

Info

Publication number
UY39714A
UY39714A UY0001039714A UY39714A UY39714A UY 39714 A UY39714 A UY 39714A UY 0001039714 A UY0001039714 A UY 0001039714A UY 39714 A UY39714 A UY 39714A UY 39714 A UY39714 A UY 39714A
Authority
UY
Uruguay
Prior art keywords
aureus
staphylococcus aureus
immunogenic compositions
vaccine compositions
aureus vaccine
Prior art date
Application number
UY0001039714A
Other languages
English (en)
Inventor
Jinquan Luo
Jeroen Geurtsen
Brian Morrow
Sergey Konstantinov
Sandeep Somani
Peter Buckley
Victor Torres
Jan Poolman
Original Assignee
Janssen Pharmaceuticals Inc
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ New York filed Critical Janssen Pharmaceuticals Inc
Publication of UY39714A publication Critical patent/UY39714A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación se refiere a composiciones inmunogénicas para inducir una respuesta inmune en un sujeto para el tratamiento y/o la prevención de una infección de Staphylococcus aureus. Las composiciones inmunogénicas que se describen en el presente documento comprenden un polipéptido A (SpA) de la proteína A de S. aureus y una leucocidina A de S. aureus (LukA) y/o polipéptido variante de leucocidina B (LukB). La presente divulgación se refiere además a métodos para generar una respuesta inmune contra S. aureus en un sujeto que implica administrar las composiciones inmunogénicas reveladas.
UY0001039714A 2021-04-02 2022-04-01 Composiciones de vacuna de staphylococcus aureus UY39714A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163170089P 2021-04-02 2021-04-02
US202163249452P 2021-09-28 2021-09-28

Publications (1)

Publication Number Publication Date
UY39714A true UY39714A (es) 2022-10-31

Family

ID=83456741

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039714A UY39714A (es) 2021-04-02 2022-04-01 Composiciones de vacuna de staphylococcus aureus

Country Status (11)

Country Link
EP (1) EP4313303A1 (es)
JP (1) JP2024512751A (es)
KR (1) KR20230165808A (es)
AU (1) AU2022246874A1 (es)
BR (1) BR112023019605A2 (es)
CA (1) CA3215751A1 (es)
IL (1) IL307178A (es)
MX (1) MX2023011640A (es)
TW (1) TW202241496A (es)
UY (1) UY39714A (es)
WO (1) WO2022212667A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431687B2 (en) * 2010-05-05 2013-04-30 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
AU2018285857B2 (en) * 2017-06-13 2022-10-06 Abvacc, Inc. Immunogenic compositions comprising Staphylococcus aureus leukocidin lukA and lukB derived polypeptides

Also Published As

Publication number Publication date
CA3215751A1 (en) 2022-10-06
JP2024512751A (ja) 2024-03-19
KR20230165808A (ko) 2023-12-05
TW202241496A (zh) 2022-11-01
AU2022246874A9 (en) 2024-01-11
MX2023011640A (es) 2023-10-13
AU2022246874A1 (en) 2023-09-21
WO2022212667A1 (en) 2022-10-06
EP4313303A1 (en) 2024-02-07
BR112023019605A2 (pt) 2023-12-05
IL307178A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
BR112018016755A2 (pt) vacina contra o vírus da zica
CL2019003091A1 (es) Terapia de combinación.
MX2020007072A (es) Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma.
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
PE20151588A1 (es) Vacuna contra el virus del dengue
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
ECSP21023398A (es) Dosis unitaria de vacuna contra el dengue y administración de esta
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
BR112021025172A2 (pt) Proteínas de fusão para vacinas de tuberculose
AR039982A1 (es) Composicion vacunal contra las alergias, metodo para su obtencion y empleo en el tratamiento de las mismas
UY39714A (es) Composiciones de vacuna de staphylococcus aureus
MX2023007306A (es) Derivados de cath2 para estimular la memoria inmune innata.
AR125291A1 (es) Composiciones de vacuna de staphylococcus aureus
BR112022007474A2 (pt) Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma
CL2022002832A1 (es) Vacuna inactivada para sars-cov-2 y preparación de la misma
WO2022150719A3 (en) Antigenic composition(s) and method(s) against porphyromonas gingivalis for the prevention and/or treatment of infection and/or diseases
BR112017028052A2 (pt) peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina
MX2022000909A (es) Vacuna contra nematodos parasitos.
PE20211376A1 (es) Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham
CO2022013715A2 (es) Vacuna inactivada contra el virus sars-cov-2